The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers.More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.Humanizovano antitelo sposobno da se specifično veže za CXCR4 ili funkcionalni fragment istog, gde je navedeni funkcionalni fragment odabran među fragmentima Fv, Fab, (Fab')2, Fab', scFv, scFv-Fc i dijatelima, naznačen time što navedeno humanizovano antitelo ili izvedeno jedinjenje ili funkcionalni fragment istog sadrži težak i lak lanac, gde navedeni težak lanac ima CDR-ove koji se sastoje od CDR-H1, CDR-H2 i CDR-H3, a navedeni lak lanac ima CDR-ove koji se sastoje od CDR-L1, CDR-L2 i CDR-L3, gde navedeni CDR-H1, CDR-H2 i CDR-H3 sadrže sekvence SEQ ID Nos. 4, 5 i 6, respektivno, a navedeni CDR-L1, CDR-L2 i CDR-L3 sadrže sekvence SEQ ID Nos. 7, 8 i 9, respektivno.Prijava sadrži još 18 patentnih zahteva.
